Advertisement

Up to Date Approaches to Treatment of Patients with Pseudomyxoma Peritonei and Peritoneal Mesothelioma

  • Amir G. Abdulaev
  • Boris E. Polotskiy
  • Mikhail M. Davydov
Chapter

Abstract

Pseudomyxoma peritonei and peritoneal mesothelioma are rare malignant diseases associated with poor prognosis. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy have been used as locoregional treatment modes for patients with perithoneal mesothelioma. Combination of these methods allows increasing treatment efficiency of this cohort of cancer patients.

Keywords

Peritoneal mesothelioma Pseudomyxoma peritonei Cytoreductive surgery Intraperitoneal chemotherapy 

References

  1. 1.
    Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A (2011) The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON 16(1):74–79PubMedGoogle Scholar
  2. 2.
    Mercier F, Bakrin N, Bartlett DL, Goere D, Quenet F, Dumont F, Heyd B (2018) Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional Cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol 25(6):1668–1675PubMedCrossRefGoogle Scholar
  3. 3.
    Fournier M, Huchon C, Ngo C, Bensaid C, Bats AS, Combe P, le FrèreBelda MA, Fournier L, Berger A, Lecuru F (2018) Morbidity of rectosigmoid resection in cytoreductive surgery for ovarian cancer. risk factor analysis. Eur J Surg Oncol 3(18):748–798Google Scholar
  4. 4.
    Perrin M, Bentivegna E, Bonneau C, Uzan C, Leary A, Pautier P, Genestie C, Morice P, Gouy S (2018) Bevacizumab does not reduce the lymphocele rate in advanced ovarian cancer after complete cytoreductive surgery. Anticancer Res 38(4):2247–2252PubMedGoogle Scholar
  5. 5.
    Coccolini F, Campanati L, Catena F et al (2015) Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 26:54–61PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Chiva LM, Gonzalez-Martin A (2015) A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol 136:130–135PubMedCrossRefGoogle Scholar
  7. 7.
    Halkia E, Spiliotis J, Sugarbaker P (2012) Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract 2012:541842PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Elias D, Honoré C, Dumont F, Ducreux M, Boige V, Malka D et al (2011) Results of systematic second look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 254:289–293PubMedCrossRefGoogle Scholar
  9. 9.
    Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A et al (2014) Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 50:332–340PubMedCrossRefGoogle Scholar
  10. 10.
    Mirnezami R, Moran BJ, Harvey K, Cecil T, Chandrakumaran K, Carr N et al (2014) Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. World J Gastroenterol 20(38):14018–14032PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Huang JY, Xu YY, Sun Z, Zhu Z, Song YX, Guo PT et al (2012) Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev 13:4379–4385PubMedCrossRefGoogle Scholar
  12. 12.
    Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y et al (2012) Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer 12:526PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Sugarbaker PH (1998) Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surger. Ludann Company, MichiganGoogle Scholar
  14. 14.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Shen P, Levine EA, Hall J et al (2003) Factors predicting survival after Intraperitoneal Hyprthermic Chemotherapy with mytomycin C after cytoreductive surgery for pts with peritoneal carcinomatosis. Arch Surg 138:26–33PubMedCrossRefGoogle Scholar
  16. 16.
    Sugarbaker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 58:96–107PubMedCrossRefGoogle Scholar
  17. 17.
    Beaujard AC, Glehen O, Caillot JL et al (2000) Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 88:2512–2519PubMedCrossRefGoogle Scholar
  18. 18.
    Fujimoto S, Takahashi M, Kobayashi K et al (1992) Cytohistologic assessment of antitumor effects of intraperitoneal hyperthermic perfusion with mitomycin C for patients peritoneal metastasis. Cancer 70:2754–2760PubMedCrossRefGoogle Scholar
  19. 19.
    Sugarbaker PH, Graves T, DeBruijn EA et al (1990) Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 50:5790–5794PubMedGoogle Scholar
  20. 20.
    Sugarbaker PH, Sweatman TW, Graves T et al (1991) Early postoperative intraperitoneal adriamycin: pharmacologic studies and a preliminary clinical report. Reg Cancer Treat 4:127–131Google Scholar
  21. 21.
    Weisberger AS, Levine B, Storaasli JP (1955) Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 159:1704–1707PubMedCrossRefGoogle Scholar
  22. 22.
    Hagiwara A, Takahashi T, Sawai K et al (1993) Clinical trials with intraperitoneal cisplatin microspheres for malignant ascites – a pilot study. AntiCancer–Drug–Des 8(6):463–470PubMedGoogle Scholar
  23. 23.
    Ng EK, Chan AC, Lee WH, et al (1999) Prospective randomized trial of intraperitoneal charcoal–adsorbed mitomycin–C as an adjuvant to resectable T3 distal gastric cancer. 3-rd international gastric cancer congress. Seoul, Apr 27–30, p 102Google Scholar
  24. 24.
    Ohgaki M, Imanishi T, Ohyama T et al (1994) The prevention of peritoneal dissemination of gastric cancer with intraperitoneal activated carbon particles absorbing mitomycin C. Gan To Kagaku Ryoho 21(13):2320–2322PubMedGoogle Scholar
  25. 25.
    Kurita A, Takashima S, Takayama T, Doihara Y (1994) Intraperitoneal chemotherapy for gastric carcinoma combined with peritoneal dissemination by intraperitoneal catheter with a subcutaneous reservoir. JpnJCancer–Chemother 21(14):2439–2444Google Scholar
  26. 26.
    Ohta K, Ohyama S, Takahashi T, Nakajima T (1999) Usefulness of intraperitoneal administration of cisplatin using a reservoir for advanced gastric cancer complicated by peritoneal dissemination. 3-rd international gastric cancer congress. Seoul, Apr 27–30, p 98Google Scholar
  27. 27.
    Roviello F (2018) The role of HIPEC in gastric cancer. Eur J Cancer 92(Suppl 2):4–5CrossRefGoogle Scholar
  28. 28.
    Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH (2001) Indication or early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 25(8):985–990PubMedCrossRefGoogle Scholar
  29. 29.
    Yoo CH, Noh SH, Shin DW, et al (1999) Early postoperative intraperitoneal chemotherapy (EPIC) for advanced gastric cancer. Proceeding of the 3-rd international gastric cancer congress. Seoul, Apr 27–30, p 103Google Scholar
  30. 30.
    Nomura E, Niki M, Fujii K, et al (2001) Efficacy of intraperitoneal and intravenous chemotherapy and upper abdominal evisceration for advanced gastric cancer. 4-th international gastric cancer congress. New York. Apr 29–May 2, p 438Google Scholar
  31. 31.
    Ruth S, Mathot RA, Sparidans RW et al (2004) Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Armacokinet 43:131–143CrossRefGoogle Scholar
  32. 32.
    Sticca RP, Dach BW (2003) Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am 12:689–701PubMedCrossRefGoogle Scholar
  33. 33.
    Oleson JR, Calderwood SK, Coughlin CT et al (1988) Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 11:368–380PubMedCrossRefGoogle Scholar
  34. 34.
    Issels RD (2008) Hyperthermia adds to chemotherapy. Eur J Cancer 44:2546–2554PubMedCrossRefGoogle Scholar
  35. 35.
    Spratt JS, Adcock RA, Muskovin M et al (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–260PubMedPubMedCentralGoogle Scholar
  36. 36.
    Elias D, Bonnay M, Puizillou JM et al (2002) Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 13:267–272PubMedCrossRefGoogle Scholar
  37. 37.
    Sugarbaker PH, Stuart OA, Carmignani CP (2006) Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 57:703–708PubMedCrossRefGoogle Scholar
  38. 38.
    Torres IJ, Litterst CL, Guarino AM (1978) Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 17:330–340PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Groose E, Walker L, Masters JR (1986) The influence of osmolarity on drug cytotoxicity in vitro. Br J Cancer 54:181Google Scholar
  40. 40.
    Kondo A, Maeta M, Oka A et al (1996) Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. Br J Cancer 73:1166–1170PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Tsujitani S, Oka A, Kondo A et al (1999) Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats. Oncology 57:77–82PubMedCrossRefGoogle Scholar
  42. 42.
    Elias D, AEl O, Bonnay M et al (2002) Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis. Oncology 63:346–352PubMedCrossRefGoogle Scholar
  43. 43.
    Pestieau SR, Schnake KJ, Stuart OA et al (2001) Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy. Cancer Chemother Pharmacol 47:269–276PubMedCrossRefGoogle Scholar
  44. 44.
    Litterst CL, Torres IJ, Arnold S et al (1982) Adsorption of antineoplastic drugs following large-volume ip administration torats. Cancer Treat Rep 66:147–155PubMedGoogle Scholar
  45. 45.
    McArdle CS, Kerr DJ, O’Gorman P et al (1994) Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 70:762–766PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Smeenk RM, Verwaal VJ, Zoetmulder FA (2006) Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei–a report of 103 procedures. Eur J Surg Oncol 32:186–190PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Shido A, Ohmura S, Yamamoto K et al (2000) Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? World J Surg 24:507–511PubMedCrossRefGoogle Scholar
  48. 48.
    Zeamari S, Floot B, Van der Vange N et al (2003) Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). Anticancer Res 23:1643–1648PubMedGoogle Scholar
  49. 49.
    Moran BJ, Mukherjee A, Sexton R (2006) Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 93:100–104PubMedCrossRefGoogle Scholar
  50. 50.
    Glehen O, Cotte E, Brigand C et al (2006) Therapeutic innovations in the management of peritoneal carcinomatosis from digestive origin: cytoreductive surgery and intraperitoneal chemotherapy. Rev Med Int 27:382–391CrossRefGoogle Scholar
  51. 51.
    Elias D, Raynard B, Boige V et al (2005) Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 90:220–225PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Kusamura S, Dominique E, Baratti D et al (2008) Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 98:247–252CrossRefGoogle Scholar
  53. 53.
    Cravioto-Villanueva A, Cavazos M, Luna-Perez P, Martinez-Gomez H, Ramirez ML, Solorzano J et al (2016) Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin. Surg Today 46(8):979–984PubMedCrossRefGoogle Scholar
  54. 54.
    Tyulyandin SA (2001) Chemotherapy for stomach cancer. Pract Oncol 7:44–51Google Scholar
  55. 55.
    Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG (2005) Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 241:300–308PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN et al (2012) Early- and long-term outcome data of patients with pseudomxyoma perontonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–2456CrossRefGoogle Scholar
  57. 57.
    Glehen O, Mohamed F, Sugarbaker PH (2004 Aug) Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Surgical Department, Centre Hospitalo-Universitaire Lyon Sud, Pierre Bénite, France. Ann Surg 240(2):278–285PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B et al (2010) Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy; Association Française de Chirurgie. Eur J Surg Oncol 36(5):7CrossRefGoogle Scholar
  59. 59.
    Gough DB, Donohue JH, Schutt AJ et al (1994) Pseudomyxoma peritonei. Long term patient survival with an aggressive regional approach. Ann Surg 219:112–119PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Glehen O, Gilly FN, Bereder JM, Quenet F, Sideris L, Mansvelt B et al (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian originby cytoreductive surgery combined with perioperative intraperitoneal chemotherapy a multi-institutional study of 1290 patients. Cancer 116(24):5608–5618PubMedCrossRefGoogle Scholar
  61. 61.
    Loungnarath R, Causeret S, Bossard N, Faheez M, Sayag Beaujard AC, Brigand C, al e (2005) Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 48:1372–1379PubMedCrossRefGoogle Scholar
  62. 62.
    Wheeler BR, Reddy SK, Kenwright D, Keating JP (2014) Treating pseudomyxoma peritonei without heated intraperitoneal chemotherapy. N Z Med J 127(1389):31–39PubMedGoogle Scholar
  63. 63.
    Sridhar K, Doria R, Raub W, Thurer R, Saldana M (1992) New strategies are needed in diffuse malignant mesothelioma. Cancer 70:2969–2979PubMedCrossRefGoogle Scholar
  64. 64.
    Antman K, Shemin R, Ryan L et al (1988) Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 6:147–153PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Piccigallo E, Jeffers L, Reddy R, Caldironi M, Parenti A, Schiff E (1988) Malignant peritoneal mesothelioma. A clinical and laparoscopic study of ten cases. Dig Dis Sci 5:633–639CrossRefGoogle Scholar
  66. 66.
    van Gelder T, Hoogsteden H, Versnel M, de Beer P, Vandenbroucke J, Planteydt H (1989) Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 43:222–227PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Antman KH, Pomfret EA, Aisner J, MacIntyre J, Osteen RT, Greenberger JS (1983) Peritoneal mesothelioma: natural history and response to chemotherapy. J Clin Oncol 1:386–391PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Garcia-Carbonero R, Paz-Ares L (2006) Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 32:676–681PubMedCrossRefGoogle Scholar
  69. 69.
    Turner K, Varghese S, Alexander HR (2012) Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Cancer Netw 10(1):49–57CrossRefGoogle Scholar
  70. 70.
    Langer CJ, Rosenblum N, Hogan M, Nash S, Bagchi P, LaCreta FP et al (1993) Intraperitoneal cisplatin and etoposide in peritoneal mesothelioma: favorable outcome with a multimodality approach. Cancer Chemother Pharmacol 32:204–208PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Markman M, Kelsen D (1992) Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118:547–550PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Manzini V, Recchia L, Cafferata M, Porta C, Siena S, Giannetta L et al (2010) Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 21:348–353CrossRefGoogle Scholar
  73. 73.
    Blackham AU, Shen P, Stewart JH, Russel GB, Levine EA (2010) Cytoreductive surgery with intraperitoneal chemotherapy for malignant peritoneal mesothelioma: mitomycin vs. cisplatin. Ann Surg Oncol 17:2720–2727PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237–6242PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M (2009) Pseudomyxoma peritonei. Ann Surg 249(2):243–249PubMedCrossRefGoogle Scholar
  76. 76.
    Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA (2010) Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol (EJSO) 36(10):997–1003CrossRefGoogle Scholar
  77. 77.
    Chua TC, Yan TD, Morris DL (2009) Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 99(2):109–113PubMedCrossRefGoogle Scholar
  78. 78.
    Robella VM, Mellano A et al (2014) Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC. Minerva Chir 69:9–15Google Scholar
  79. 79.
    Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA (2014) Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 21(4):1159–1165PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT et al (2015) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol 22(5):1686–1693PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Moran BJ (2006) Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf) 28:375–378CrossRefGoogle Scholar
  82. 82.
    Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94:1408–1414PubMedCrossRefGoogle Scholar
  83. 83.
    Yan TD, Links M, Fransi S et al (2007) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy a journey to becoming a nationally funded peritonectomy center. Ann Surg Oncol 14:2270–2280PubMedCrossRefGoogle Scholar
  84. 84.
    Sugarbaker PH, Welch LS, Mohamed F et al (2003) A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12:605–621PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Park BJ, Alexander HR, Libutti SK et al (1999) Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 6:582–590PubMedCrossRefGoogle Scholar
  86. 86.
    Deraco M, Nonaka D, Baratti D et al (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13:229–237PubMedCrossRefGoogle Scholar
  87. 87.
    Yan TD, Yoo D, Sugarbaker P (2006) Significance of lymphnodemetastasisinpatientswithdiffusemalignantperitonealmesothelioma. Eur J Surg Oncol 32:948–953PubMedCrossRefGoogle Scholar
  88. 88.
    Yan TD, Brun E, Carlos A et al (2007) Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 14:41–49PubMedCrossRefGoogle Scholar
  89. 89.
    Nonaka D, Kusamura S, Baratti D et al (2005) Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution. Cancer 104:2181–2188PubMedCrossRefGoogle Scholar
  90. 90.
    Brigand C, Monneuse O, Mohamed F et al (2006) Malignant peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal chemohyperthermia: results of a prospective study. Ann Surg Oncol 13:405–412PubMedCrossRefGoogle Scholar
  91. 91.
    Loggie BW, Fleming RA, McQuellon RP et al (2001) Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67:999–1003PubMedGoogle Scholar
  92. 92.
    Yan TD, Popa E, Brun E et al (2006) Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 93:1536–1542PubMedCrossRefGoogle Scholar
  93. 93.
    López-Basave HN, Morales-Vásquez F, Ruiz Molina JM et al (2011) Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: national cancer institute, Mexico city, Mexico. ISRN Oncol 2011:526384PubMedPubMedCentralGoogle Scholar
  94. 94.
    Mohamed F, Moran BJ (2009) Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy. Cancer J 15:196–199PubMedCrossRefGoogle Scholar
  95. 95.
    Feldman AL, Libutti SK, Pingpank JF et al (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21:4560–4567PubMedCrossRefGoogle Scholar
  96. 96.
    Kusamura S, Younan R, Baratti D et al (2006) Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of peritoneal surface malignancies: analysis of morbidity and mortality in 209 cases treated with closed abdomen technique. Cancer 106:1144–1153PubMedCrossRefGoogle Scholar
  97. 97.
    Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Bozzetti F, Braga M, Gianotti L et al (2001) Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. Lancet 358:1487–1492PubMedCrossRefGoogle Scholar
  99. 99.
    Younan R, Kusamura S, Baratti D et al (2005) Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol 12:910–918PubMedCrossRefGoogle Scholar
  100. 100.
    Roviello F, Marrelli D, Neri A et al (2006) Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity. World J Surg 30(11):2033–2040PubMedCrossRefGoogle Scholar
  101. 101.
    Younan R, Kusamura S, Baratti D et al (2008) Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol 98:253–257PubMedCrossRefGoogle Scholar
  102. 102.
    van Leeuwen BL, Graf W, Pahlman L, Mahteme H (2008) Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcinomatosis. Ann Surg Oncol 15(3):745–753Google Scholar
  103. 103.
    Rufian S, Munoz-Casares F, Bricefiо J et al (2006) Radical surgery- peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. Ann Surg Oncol 94:316–324PubMedCrossRefGoogle Scholar
  104. 104.
    Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL (2008) Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 15(3):754–763PubMedCrossRefGoogle Scholar
  105. 105.
    Clemente-Gutiérrez U, Garza-Gangemi A, Trejo-Gómez G, Medina-Franco H (2015) Morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy at a tertiary care center: initial experience. Rev Investig Clin 67:39–45Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Amir G. Abdulaev
    • 1
  • Boris E. Polotskiy
    • 1
  • Mikhail M. Davydov
    • 1
  1. 1.Oncologist and Surgeon Thoracic Research DepartmentN.N. Blokhin National Medical Research CenterMoscowRussia

Personalised recommendations